THE FULL BREAKDOWN
CBD and CBG are both non-psychoactive cannabinoids found in cannabis, but they differ substantially in plant biology, receptor mechanism, and research applications.
CBD is the second-most-abundant cannabinoid in cannabis after THC. Mature cannabis can produce 8–20% CBD in CBD-rich strains. CBD is also the most thoroughly researched non-psychoactive cannabinoid — Epidiolex (FDA-approved CBD medication) is the only FDA-approved cannabinoid drug. Beyond epilepsy, CBD research covers anxiety, sleep, inflammation, and pain modulation.
CBG is the "mother cannabinoid" because its acid-form precursor CBGa is the upstream molecule from which most other cannabinoids are enzymatically synthesized during plant growth. By harvest, most CBGa has converted to other cannabinoids — leaving most cannabis with under 1% CBG. Specialty CBG-dominant cultivars (10%+ CBG) exist but are rare.
Mechanistically, CBD acts as a negative allosteric modulator of CB1 (modulates THC effects when present together). CBG is a low-affinity CB1 ligand without significant modulator activity. Their non-receptor effects differ: CBD interacts with serotonin (5-HT1A), TRPV1, and adenosine receptors; CBG primarily interacts with α2-adrenergic receptors and shows direct anti-inflammatory effects.
For anxiety, sleep, and seizure applications, CBD has the research evidence. For anti-inflammatory and antibacterial applications, CBG is the early front-runner. Both are non-psychoactive, both are federally legal under the 2018 Farm Bill, both are safe for daily use.
